Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge The impact of China’s latest covid-19 surge heads the… Centralised Diagnostics (CEDx) | Covid-19 testing | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx)
Most common cancer biomarkers for Europe NGS testing: RAS, BRAF, EGFR Most-commonly tested cancer biomarkers using NGS in Europe… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Larger gene panels are the predominant NGS testing strategy in EU5 Larger gene panels are the predominant NGS testing strategy… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Europe: precision medicine and access to NGS cancer biomarker testing Precision medicine and access to NGS cancer biomarker… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019 Proportion of cancer biomarker testing done with NGS… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)
Tissue-based companion diagnostics market to grow for the most common cancers in China Companion diagnostics (CDx) use is growing as the cancer… In-vitro diagnostics | Tissue Diagnostics (TDx) | Asia | IVD Gateway | Tissue Diagnostics (TDx)
Digital pathology growth to outpace broader TDx market in several countries Laboratories that adopt digital pathology, support the… In-vitro diagnostics | Tissue Diagnostics (TDx) | IVD Gateway | Tissue Diagnostics (TDx)
Cancer and tissue diagnostics market outlook Tissue diagnostics (TDx) play an important role in improving… Cancer diagnostics | In-vitro diagnostics | Tissue Diagnostics (TDx) | Americas | Asia | Europe | IVD Gateway | Tissue Diagnostics (TDx)
Future of Pathology: Four Growth Areas in Tissue Diagnostics Various technologies and advancements in tissue diagnostics… In-vitro diagnostics | Tissue Diagnostics (TDx) | Global | IVD Gateway | Tissue Diagnostics (TDx)